Literature DB >> 6743423

Beneficial effects of diltiazem in coronary artery disease.

J Kenny, K Daly, G Bergman, S Kerkez, D E Jewitt.   

Abstract

The effects of the new calcium channel blocking agent diltiazem were evaluated in 11 patients with stable angina pectoris and confirmed obstructive coronary artery disease at rest and during rapid atrial pacing. Symptomatic, metabolic, coronary, and systemic haemodynamic indices were monitored at rest and during pacing induced ischaemia. At rest, after the administration of intravenous diltiazem, potent vasodilator effects were observed with a significant fall in mean blood pressure and an increase in cardiac index. Importantly, however, the systemic vasodilator effect of diltiazem was associated with no significant increase in heart rate. During pacing there was similar decrease in mean blood pressure after diltiazem, and mean pacing time to angina increased significantly. Three patients did not develop angina on repeat pacing. Coupled with an improved pacing time to angina there was a significant improvement in myocardial lactate extraction during pacing, changing from lactate production to lactate extraction after diltiazem. This study confirms the antianginal effects of diltiazem and suggests that this agent may have advantages in the management of angina pectoris. The results suggest that diltiazem may exert its beneficial effect not only by reducing afterload reduction but also by a direct metabolic effect on the myocardium.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743423      PMCID: PMC481584          DOI: 10.1136/hrt.52.1.53

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  19 in total

1.  Improvement of myocardial metabolism in coronary arterial disease by beta-blockade.

Authors:  G Jackson; L Atkinson; S Oram
Journal:  Br Heart J       Date:  1977-08

2.  Measurement of coronary sinus blood flow by continuous thermodilution in man.

Authors:  W Ganz; K Tamura; H S Marcus; R Donoso; S Yoshida; H J Swan
Journal:  Circulation       Date:  1971-08       Impact factor: 29.690

3.  Coronary circulation during pacing-induced tachycardia.

Authors:  S Holmberg; E Varnauskas
Journal:  Acta Med Scand       Date:  1971-12

4.  Pharmacological studies on a new l,5-benzothiazepine derivative (CRD-401).

Authors:  M Sato; T Nagao; I Yamaguchi; H Nakajima; A Kiyomoto
Journal:  Arzneimittelforschung       Date:  1971-09

5.  Effects of nifedipine after intravenous and intracoronary administration.

Authors:  M Kaltenbach; W Schulz; G Kober
Journal:  Am J Cardiol       Date:  1979-10-22       Impact factor: 2.778

6.  Antianginal and myocardial metabolic properties of verapamil in coronary artery disease.

Authors:  J Ferlinz; M E Turbow
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

Review 7.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

8.  Responses of coronary collateral flow and dependent myocardial mechanical function to the calcium antagonist, diltiazem.

Authors:  D Franklin; R W Millard; T Nagao
Journal:  Chest       Date:  1980-07       Impact factor: 9.410

9.  Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.

Authors:  V B Subramanian; A Lahiri; R Paramasivan; E B Raftery
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

10.  Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

Authors:  P Lynch; H Dargie; S Krikler; D Krikler
Journal:  Br Med J       Date:  1980-07-19
View more
  2 in total

Review 1.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 2.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.